<DOC>
	<DOCNO>NCT01950819</DOCNO>
	<brief_summary>This 2-year , randomize , multicenter , open-label , 2-arm study evaluate graft function everolimus reduce CNI versus MPA standard CNI adult de novo renal transplant recipient .</brief_summary>
	<brief_title>Advancing Renal TRANSplant eFficacy Safety Outcomes With eveRolimus-based regiMen ( TRANSFORM )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>1 . Written inform consent obtain . 2 . Subject randomize within 24 hr completion transplant surgery . 3 . Recipient kidney cold ischemia time &lt; 30 hour . 4 . Recipient primary ( secondary , first graft lose due immunological reason ) renal transplant decease heart beating , live unrelated , live related nonhuman leukocyte antigen identical expand criterion donor . 1 . Subject unable tolerate oral medication time randomization . 2 . Use investigational drug time enrollment . 3 . History hypersensitivity study drug drug similar chemical class . 4 . Multiorgan transplant recipient . 5 . Recipient ABO incompatible allograft complementdependent lymphocytotoxic ( CDC ) crossmatch positive transplant . 6 . Subject high immunological risk rejection determine local practice assessment antidonor reactivity e.g . high PRA , presence preexist DSA . 7 . Subject HIVpositive . 8 . HBsAg and/or HCV positive subject evidence elevate LFTs ( ALT/AST level ≥ 2.5 time ULN ) . Viral serology result obtain within 6 month prior randomization acceptable . 9 . Recipient kidney donor test positive human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) antihepatitis C virus ( HCV ) . 10 . Subject BMI great 35 . 11 . Subject severe systemic infection , current within two week prior randomization . 12 . Subject require systemic anticoagulation . 13 . History malignancy organ system . 14 . Subject severe restrictive obstructive pulmonary disorder . 15 . Subject severe hypercholesterolemia hypertriglyceridemia control . 16 . Subject white blood cell ( WBC ) count ≤ 2,000 /mm3 platelet count ≤ 50,000 /mm3 . 17 . Pregnant nursing ( lactate ) woman . 18 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>kidney failure</keyword>
	<keyword>dialysis</keyword>
	<keyword>renal failure</keyword>
	<keyword>transplantation</keyword>
</DOC>